ID   SHH_HUMAN               Reviewed;         462 AA.
AC   Q15465; A4D247; Q75MC9;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   22-JUL-2015, entry version 183.
DE   RecName: Full=Sonic hedgehog protein;
DE            Short=SHH;
DE   AltName: Full=HHG-1;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein N-product;
DE   Contains:
DE     RecName: Full=Sonic hedgehog protein C-product;
DE   Flags: Precursor;
GN   Name=SHH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Fetal lung;
RX   PubMed=7590746; DOI=10.1006/geno.1995.1104;
RA   Marigo V., Roberts D.J., Lee S.M.K., Tsukurov O., Levi T.,
RA   Gastier J.M., Epstein D.J., Gilbert D.J., Copeland N.G., Seidman C.E.,
RA   Jenkins N.A., Seidman J.G., McMahon A.P., Tabin C.;
RT   "Cloning, expression, and chromosomal location of SHH and IHH: two
RT   human homologues of the Drosophila segment polarity gene hedgehog.";
RL   Genomics 28:44-51(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Tate G., Kishimoto K., Mitsuya T.;
RT   "Expression of Sonic hedgehog and its receptor Patched/Smoothened in
RT   human cancer cell lines and embryonic organs.";
RL   J. Biochem. Mol. Biol. Biophys. 4:27-34(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NIEHS SNPs program;
RL   Submitted (SEP-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S.,
RA   Kwasnicka D., Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z.,
RA   Lu F., Zeesman S., Nowaczyk M.J., Teshima I., Chitayat D., Shuman C.,
RA   Weksberg R., Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J.,
RA   Rahman N., Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F.,
RA   Belloni E., Shaffer L.G., Pober B., Morton C.C., Gusella J.F.,
RA   Bruns G.A.P., Korf B.R., Quade B.J., Ligon A.H., Ferguson H.,
RA   Higgins A.W., Leach N.T., Herrick S.R., Lemyre E., Farra C.G.,
RA   Kim H.-G., Summers A.M., Gripp K.W., Roberts W., Szatmari P.,
RA   Winsor E.J.T., Grzeschik K.-H., Teebi A., Minassian B.A., Kere J.,
RA   Armengol L., Pujana M.A., Estivill X., Wilson M.D., Koop B.F.,
RA   Tosi S., Moore G.E., Boright A.P., Zlotorynski E., Kerem B.,
RA   Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W.,
RA   Mural R.J., Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [6]
RP   PROTEIN SEQUENCE OF 24-32, PALMITOYLATION AT CYS-24, CHOLESTERYLATION,
RP   MUTAGENESIS OF CYS-24, AND MASS SPECTROMETRY.
RX   PubMed=9593755; DOI=10.1074/jbc.273.22.14037;
RA   Pepinsky R.B., Zeng C., Wen D., Rayhorn P., Baker D.P., Williams K.P.,
RA   Bixler S.A., Ambrose C.M., Garber E.A., Miatkowski K., Taylor F.R.,
RA   Wang E.A., Galdes A.;
RT   "Identification of a palmitic acid-modified form of human Sonic
RT   hedgehog.";
RL   J. Biol. Chem. 273:14037-14045(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 119-167.
RX   PubMed=7720571;
RA   Chang D.T., Lopez A., von Kessler D.P., Chiang C., Simandl B.K.,
RA   Zhao R., Seldin M.F., Fallon J.F., Beachy P.A.;
RT   "Products, genetic linkage and limb patterning activity of a murine
RT   hedgehog gene.";
RL   Development 120:3339-3353(1994).
RN   [8]
RP   INVOLVEMENT IN TPTPS.
RX   PubMed=12837695; DOI=10.1093/hmg/ddg180;
RA   Lettice L.A., Heaney S.J.H., Purdie L.A., Li L., de Beer P.,
RA   Oostra B.A., Goode D., Elgar G., Hill R.E., de Graaff E.;
RT   "A long-range Shh enhancer regulates expression in the developing limb
RT   and fin and is associated with preaxial polydactyly.";
RL   Hum. Mol. Genet. 12:1725-1735(2003).
RN   [9]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-278.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [10]
RP   INVOLVEMENT IN TPTPS.
RX   PubMed=18417549; DOI=10.1136/jmg.2008.057646;
RA   Sun M., Ma F., Zeng X., Liu Q., Zhao X.-L., Wu F.-X., Wu G.-P.,
RA   Zhang Z.-F., Gu B., Zhao Y.-F., Tian S.-H., Lin B., Kong X.-Y.,
RA   Zhang X.-L., Yang W., Lo W.H.-Y., Zhang X.;
RT   "Triphalangeal thumb-polysyndactyly syndrome and syndactyly type IV
RT   are caused by genomic duplications involving the long range, limb-
RT   specific SHH enhancer.";
RL   J. Med. Genet. 45:589-595(2008).
RN   [11]
RP   INVOLVEMENT IN THYP.
RX   PubMed=19847792; DOI=10.1002/humu.21142;
RA   Wieczorek D., Pawlik B., Li Y., Akarsu N.A., Caliebe A., May K.J.,
RA   Schweiger B., Vargas F.R., Balci S., Gillessen-Kaesbach G.,
RA   Wollnik B.;
RT   "A specific mutation in the distant sonic hedgehog (SHH) cis-regulator
RT   (ZRS) causes Werner mesomelic syndrome (WMS) while complete ZRS
RT   duplications underlie Haas type polysyndactyly and preaxial
RT   polydactyly (PPD) with or without triphalangeal thumb.";
RL   Hum. Mutat. 31:81-89(2010).
RN   [12]
RP   INVOLVEMENT IN LSS.
RX   PubMed=24456159; DOI=10.1111/cge.12352;
RA   Lohan S., Spielmann M., Doelken S.C., Floettmann R., Muhammad F.,
RA   Baig S.M., Wajid M., Huelsemann W., Habenicht R., Kjaer K.W.,
RA   Patil S.J., Girisha K.M., Abarca-Barriga H.H., Mundlos S.,
RA   Klopocki E.;
RT   "Microduplications encompassing the Sonic hedgehog limb enhancer ZRS
RT   are associated with Haas-type polysyndactyly and Laurin-Sandrow
RT   syndrome.";
RL   Clin. Genet. 86:318-325(2014).
RN   [13]
RP   INVOLVEMENT IN THYP.
RX   PubMed=24965254; DOI=10.1038/jhg.2014.50;
RA   Norbnop P., Srichomthong C., Suphapeetiporn K., Shotelersuk V.;
RT   "ZRS 406A>G mutation in patients with tibial hypoplasia, polydactyly
RT   and triphalangeal first fingers.";
RL   J. Hum. Genet. 59:467-470(2014).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 25-197 IN COMPLEX WITH ZINC
RP   IONS, FUNCTION, AND DOMAIN.
RX   PubMed=10753901; DOI=10.1074/jbc.275.15.10995;
RA   Pepinsky R.B., Rayhorn P., Day E.S., Dergay A., Williams K.P.,
RA   Galdes A., Taylor F.R., Boriack-Sjodin P.A., Garber E.A.;
RT   "Mapping sonic hedgehog-receptor interactions by steric
RT   interference.";
RL   J. Biol. Chem. 275:10995-11001(2000).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (3.01 ANGSTROMS) OF 29-197 IN COMPLEX WITH HHIP;
RP   ZINC AND CALCIUM IONS, DOMAIN, AND INTERACTION WITH HHIP.
RX   PubMed=19561609; DOI=10.1038/nsmb.1632;
RA   Bosanac I., Maun H.R., Scales S.J., Wen X., Lingel A., Bazan J.F.,
RA   de Sauvage F.J., Hymowitz S.G., Lazarus R.A.;
RT   "The structure of SHH in complex with HHIP reveals a recognition role
RT   for the Shh pseudo active site in signaling.";
RL   Nat. Struct. Mol. Biol. 16:691-697(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.83 ANGSTROMS) OF 29-197 IN COMPLEX WITH
RP   MONOCLONAL ANTIBODY; ZINC AND CALCIUM IONS, SUBCELLULAR LOCATION, AND
RP   DOMAIN.
RX   PubMed=20504762; DOI=10.1074/jbc.M110.112284;
RA   Maun H.R., Wen X., Lingel A., de Sauvage F.J., Lazarus R.A.,
RA   Scales S.J., Hymowitz S.G.;
RT   "Hedgehog pathway antagonist 5E1 binds hedgehog at the pseudo-active
RT   site.";
RL   J. Biol. Chem. 285:26570-26580(2010).
RN   [17]
RP   VARIANTS HPE3 ARG-31; GLY-117 AND ARG-117.
RX   PubMed=8896572; DOI=10.1038/ng1196-357;
RA   Roessler E., Belloni E., Gaudenz K., Jay P., Berta P., Scherer S.W.,
RA   Tsui L.-C., Muenke M.;
RT   "Mutations in the human Sonic hedgehog gene cause holoprosencephaly.";
RL   Nat. Genet. 14:357-360(1996).
RN   [18]
RP   VARIANTS HPE3 ARG-31; GLY-117; ARG-117; GLU-224; THR-226 AND THR-383.
RX   PubMed=9302262; DOI=10.1093/hmg/6.11.1847;
RA   Roessler E., Belloni E., Gaudenz K., Vargas F., Scherer S.W.,
RA   Tsui L.-C., Muenke M.;
RT   "Mutations in the C-terminal domain of Sonic hedgehog cause
RT   holoprosencephaly.";
RL   Hum. Mol. Genet. 6:1847-1853(1997).
RN   [19]
RP   VARIANTS HPE3 HIS-100; GLN-188 AND ASN-222.
RX   PubMed=10441331; DOI=10.1093/hmg/8.9.1683;
RA   Odent S., Atti-Bitach T., Blayau M., Mathieu M., Aug J.,
RA   Delezo de A.L., Gall J.Y., Le Marec B., Munnich A., David V.,
RA   Vekemans M.;
RT   "Expression of the Sonic hedgehog (SHH) gene during early human
RT   development and phenotypic expression of new mutations causing
RT   holoprosencephaly.";
RL   Hum. Mol. Genet. 8:1683-1689(1999).
RN   [20]
RP   VARIANTS HPE3 VAL-88; LYS-115; ARG-236; 263-ARG--ALA-269 DEL; ASP-290;
RP   ALA-424 AND LEU-436.
RX   PubMed=10556296; DOI=10.1093/hmg/8.13.2479;
RA   Nanni L., Ming J.E., Bocian M., Steinhaus K., Bianchi D.W.,
RA   Die-Smulders C., Giannotti A., Imaizumi K., Jones K.L., Campo M.D.,
RA   Martin R.A., Meinecke P., Pierpont M.E.M., Robin N.H., Young I.D.,
RA   Roessler E., Muenke M.;
RT   "The mutational spectrum of the sonic hedgehog gene in
RT   holoprosencephaly: SHH mutations cause a significant proportion of
RT   autosomal dominant holoprosencephaly.";
RL   Hum. Mol. Genet. 8:2479-2488(1999).
RN   [21]
RP   VARIANT SMMCI PHE-111.
RX   PubMed=11471164;
RX   DOI=10.1002/1096-8628(20010722)102:1<1::AID-AJMG1336>3.0.CO;2-U;
RA   Nanni L., Ming J.E., Du Y., Hall R.K., Aldred M., Bankier A.,
RA   Muenke M.;
RT   "SHH mutation is associated with solitary median maxillary central
RT   incisor: a study of 13 patients and review of the literature.";
RL   Am. J. Med. Genet. 102:1-10(2001).
RN   [22]
RP   VARIANTS HPE3 PRO-140 AND PHE-183.
RX   PubMed=11479728; DOI=10.1007/s004390100537;
RA   Orioli I.M., Castilla E.E., Ming J.E., Nazer J., Burle de Aguiar M.J.,
RA   Llerena J.C., Muenke M.;
RT   "Identification of novel mutations in SHH and ZIC2 in a South American
RT   (ECLAMC) population with holoprosencephaly.";
RL   Hum. Genet. 109:1-6(2001).
RN   [23]
RP   VARIANT MCOPCB5 401-SER--GLY-408 DEL.
RX   PubMed=12503095; DOI=10.1002/ajmg.a.10884;
RA   Schimmenti L.A., de la Cruz J., Lewis R.A., Karkera J.D.,
RA   Manligas G.S., Roessler E., Muenke M.;
RT   "Novel mutation in sonic hedgehog in non-syndromic colobomatous
RT   microphthalmia.";
RL   Am. J. Med. Genet. A 116:215-221(2003).
RN   [24]
RP   VARIANT SMMCI ALA-332.
RX   PubMed=15103725; DOI=10.1002/ajmg.a.20685;
RA   Garavelli L., Zanacca C., Caselli G., Banchini G., Dubourg C.,
RA   David V., Odent S., Gurrieri F., Neri G.;
RT   "Solitary median maxillary central incisor syndrome: clinical case
RT   with a novel mutation of sonic hedgehog.";
RL   Am. J. Med. Genet. A 127:93-95(2004).
RN   [25]
RP   VARIANTS HPE3 ALA-27; ILE-267 AND THR-373.
RX   PubMed=15107988; DOI=10.1007/s00431-004-1459-0;
RA   Hehr U., Gross C., Diebold U., Wahl D., Beudt U., Heidemann P.,
RA   Hehr A., Mueller D.;
RT   "Wide phenotypic variability in families with holoprosencephaly and a
RT   sonic hedgehog mutation.";
RL   Eur. J. Pediatr. 163:347-352(2004).
RN   [26]
RP   VARIANTS HPE3 THR-6; HIS-100; 106-LEU-ASN-107 DEL; ASP-110; ARG-150;
RP   176-GLU--LYS-178 DEL; GLN-188; ASN-222; PRO-271; ALA-332; GLN-347;
RP   THR-354 AND PRO-381.
RX   PubMed=15221788; DOI=10.1002/humu.20056;
RA   Dubourg C., Lazaro L., Pasquier L., Bendavid C., Blayau M.,
RA   Le Duff F., Durou M.-R., Odent S., David V.;
RT   "Molecular screening of SHH, ZIC2, SIX3, and TGIF genes in patients
RT   with features of holoprosencephaly spectrum: mutation review and
RT   genotype-phenotype correlations.";
RL   Hum. Mutat. 24:43-51(2004).
RN   [27]
RP   VARIANT HPE3 ASN-111.
RX   PubMed=15942952; DOI=10.1002/ajmg.a.30624;
RA   El-Jaick K.B., Brunoni D., Castilla E.E., Moreira M.A., Orioli I.M.;
RT   "SHH Ile111Asp in alobar holoprosencephaly in a proposita, whose
RT   mother had only a solitary median maxillary incisor.";
RL   Am. J. Med. Genet. A 136:345-345(2005).
RN   [28]
RP   VARIANT HPE3 GLN-140.
RX   PubMed=15942953; DOI=10.1002/ajmg.a.30625;
RA   Ribeiro L.A., Richieri-Costa A.;
RT   "Single median maxillary central incisor, hypophyseal tumor, and SHH
RT   mutation.";
RL   Am. J. Med. Genet. A 136:346-347(2005).
RN   [29]
RP   CHARACTERIZATION OF VARIANTS HPE3 ARG-31; VAL-88; HIS-100; LYS-115;
RP   ARG-117; GLY-117 AND GLN-188.
RX   PubMed=16282375; DOI=10.1073/pnas.0507848102;
RA   Maity T., Fuse N., Beachy P.A.;
RT   "Molecular mechanisms of Sonic hedgehog mutant effects in
RT   holoprosencephaly.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:17026-17031(2005).
RN   [30]
RP   VARIANTS HPE3 GLN-140; PRO-218 AND TYR-363.
RX   PubMed=17001669; DOI=10.1002/ajmg.a.31378;
RA   Richieri-Costa A., Ribeiro L.A.;
RT   "Holoprosencephaly-like phenotype: clinical and genetic
RT   perspectives.";
RL   Am. J. Med. Genet. A 140:2587-2593(2006).
RN   [31]
RP   VARIANTS HPE3 THR-6; PRO-17; LEU-26; ALA-27; ARG-31; PRO-39; LYS-53;
RP   VAL-83; PHE-84; VAL-88; HIS-100; ARG-102; TYR-102; 106-LEU-ASN-107
RP   DEL; PHE-109; THR-110; ASP-110; PHE-111; ASN-111; LYS-115; GLY-117;
RP   ARG-117; MET-124; LYS-136; PRO-140; GLN-140; ASP-143; PRO-144;
RP   ASN-147; ARG-150; LYS-150; ARG-156; CYS-170; HIS-171; 176-GLU--LYS-178
RP   DEL; ARG-183; PHE-183; TYR-183; LEU-184; GLN-188; GLU-196;
RP   196-GLY--PRO-200 DEL; VAL-197; SER-198; PHE-198; PRO-218; ASN-222;
RP   GLU-224; THR-226; VAL-231; GLY-232; PRO-234; ARG-236; ASN-236;
RP   VAL-241; LEU-241; ASN-255; 263-ARG--ALA-269 DEL; ILE-267; PRO-271;
RP   GLU-275; TRP-280; ASP-290; ALA-296; CYS-310; SER-321; ALA-332;
RP   VAL-346; ARG-347; GLN-347; LEU-347; THR-354; LEU-362; TYR-363;
RP   CYS-364; THR-373; ARG-374; ASP-376; SER-377; 378-ALA--PHE-380 DEL;
RP   PRO-381; PRO-382; THR-383; THR-391; 402-GLY--GLY-409 DEL;
RP   405-ASP--GLY-409 DEL; GLY-411 INS; ALA-416; ALA-424; ASN-435; LEU-436
RP   AND ARG-456.
RX   PubMed=19603532; DOI=10.1002/humu.21090;
RA   Roessler E., El-Jaick K.B., Dubourg C., Velez J.I., Solomon B.D.,
RA   Pineda-Alvarez D.E., Lacbawan F., Zhou N., Ouspenskaia M.,
RA   Paulussen A., Smeets H.J., Hehr U., Bendavid C., Bale S., Odent S.,
RA   David V., Muenke M.;
RT   "The mutational spectrum of holoprosencephaly-associated changes
RT   within the SHH gene in humans predicts loss-of-function through either
RT   key structural alterations of the ligand or its altered synthesis.";
RL   Hum. Mutat. 30:E921-E935(2009).
CC   -!- FUNCTION: Intercellular signal essential for a variety of
CC       patterning events during development: signal produced by the
CC       notochord that induces ventral cell fate in the neural tube and
CC       somites, and the polarizing signal for patterning of the anterior-
CC       posterior axis of the developing limb bud. Displays both floor
CC       plate- and motor neuron-inducing activity. The threshold
CC       concentration of N-product required for motor neuron induction is
CC       5-fold lower than that required for floor plate induction.
CC       Activates the transcription of target genes by interacting with
CC       its receptor PTCH1 to prevent normal inhibition by PTCH1 on the
CC       constitutive signaling activity of SMO (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBUNIT: Interacts with HHATL/GUP1 which negatively regulates
CC       HHAT-mediated palmitoylation of the SHH N-terminus. N-product is
CC       active as a multimer. Interacts with BOC and CDON (By similarity).
CC       Interacts with HHIP. {ECO:0000250, ECO:0000269|PubMed:10753901,
CC       ECO:0000269|PubMed:19561609, ECO:0000269|PubMed:20504762}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein C-product: Secreted,
CC       extracellular space {ECO:0000250}. Note=The C-terminal peptide
CC       diffuses from the cell. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Sonic hedgehog protein N-product: Cell
CC       membrane {ECO:0000250}; Lipid-anchor {ECO:0000250}. Cell membrane.
CC       Note=The N-product either remains associated with lipid rafts at
CC       the cell surface, or forms freely diffusible active multimers with
CC       its hydrophobic lipid-modified N- and C-termini buried inside.
CC       {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in fetal intestine, liver, lung, and
CC       kidney. Not expressed in adult tissues.
CC   -!- DOMAIN: The sonic hedgehog protein N-product binds calcium and
CC       zinc ions; this stabilizes the protein fold and is essential for
CC       protein-protein interactions mediated by this domain.
CC       {ECO:0000269|PubMed:10753901, ECO:0000269|PubMed:19561609,
CC       ECO:0000269|PubMed:20504762}.
CC   -!- PTM: The C-terminal domain displays an autoproteolysis activity
CC       and a cholesterol transferase activity. Both activities result in
CC       the cleavage of the full-length protein and covalent attachment of
CC       a cholesterol moiety to the C-terminal of the newly generated N-
CC       terminal fragment (N-product). The N-product is the active species
CC       in both local and long-range signaling, whereas the C-product has
CC       no signaling activity.
CC   -!- PTM: Cholesterylation is required for N-product targeting to lipid
CC       rafts and multimerization. {ECO:0000250}.
CC   -!- PTM: N-palmitoylation of Cys-24 by HHAT is required for N-product
CC       multimerization and full activity. {ECO:0000250}.
CC   -!- MASS SPECTROMETRY: Mass=19.560; Method=Electrospray; Range=24-197;
CC       Note=Soluble N-product, purified from insect cells.;
CC       Evidence={ECO:0000269|PubMed:9593755};
CC   -!- MASS SPECTROMETRY: Mass=20.167; Method=Electrospray; Range=24-197;
CC       Note=Membrane-bound N-product, purified from insect cells.;
CC       Evidence={ECO:0000269|PubMed:9593755};
CC   -!- DISEASE: Microphthalmia, isolated, with coloboma, 5 (MCOPCB5)
CC       [MIM:611638]: A disorder of eye formation, ranging from small size
CC       of a single eye to complete bilateral absence of ocular tissues.
CC       Ocular abnormalities like opacities of the cornea and lens,
CC       scaring of the retina and choroid, and other abnormalities may
CC       also be present. Ocular colobomas are a set of malformations
CC       resulting from abnormal morphogenesis of the optic cup and stalk,
CC       and the fusion of the fetal fissure (optic fissure).
CC       {ECO:0000269|PubMed:12503095}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Holoprosencephaly 3 (HPE3) [MIM:142945]: A structural
CC       anomaly of the brain, in which the developing forebrain fails to
CC       correctly separate into right and left hemispheres.
CC       Holoprosencephaly is genetically heterogeneous and associated with
CC       several distinct facies and phenotypic variability. The majority
CC       of holoprosencephaly type 3 cases are apparently sporadic,
CC       although clear examples of autosomal dominant inheritance have
CC       been described. {ECO:0000269|PubMed:10441331,
CC       ECO:0000269|PubMed:10556296, ECO:0000269|PubMed:11479728,
CC       ECO:0000269|PubMed:15107988, ECO:0000269|PubMed:15221788,
CC       ECO:0000269|PubMed:15942952, ECO:0000269|PubMed:15942953,
CC       ECO:0000269|PubMed:17001669, ECO:0000269|PubMed:19603532,
CC       ECO:0000269|PubMed:8896572, ECO:0000269|PubMed:9302262}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Solitary median maxillary central incisor (SMMCI)
CC       [MIM:147250]: Rare dental anomaly characterized by the congenital
CC       absence of one maxillary central incisor.
CC       {ECO:0000269|PubMed:11471164, ECO:0000269|PubMed:15103725}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Triphalangeal thumb-polysyndactyly syndrome (TPTPS)
CC       [MIM:174500]: Autosomal dominant syndrome. It is characterized by
CC       a wide spectrum of pre- and post-axial abnormalities due to
CC       altered SHH expression pattern during limb development.
CC       {ECO:0000269|PubMed:12837695, ECO:0000269|PubMed:18417549}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Mutations located in intron 5 of LMBR1 disrupt a
CC       long-range, cis-regulatory element of SHH expression.
CC   -!- DISEASE: Preaxial polydactyly 2 (PPD2) [MIM:174500]: Polydactyly
CC       consists of duplication of the distal phalanx. The thumb in PPD2
CC       is usually opposable and possesses a normal metacarpal. Note=The
CC       gene represented in this entry is involved in disease
CC       pathogenesis. Mutations located in intron 5 of LMBR1 disrupt a
CC       long-range, cis-regulatory element of SHH and result in abnormal,
CC       ectopic SHH expression with pathological consequences
CC       (PubMed:12837695). {ECO:0000269|PubMed:12837695}.
CC   -!- DISEASE: Hypoplasia or aplasia of tibia with polydactyly (THYP)
CC       [MIM:188740]: An autosomal dominant disease characterized by
CC       hypoplastic or absent tibia, and polydactyly.
CC       {ECO:0000269|PubMed:19847792, ECO:0000269|PubMed:24965254}.
CC       Note=The gene represented in this entry is involved in disease
CC       pathogenesis. Mutations located in intron 5 of LMBR1 disrupt a
CC       long-range, cis-regulatory element of SHH and result in abnormal,
CC       ectopic SHH expression with pathological consequences.
CC       {ECO:0000303|PubMed:19847792, ECO:0000303|PubMed:24965254}.
CC   -!- DISEASE: Laurin-Sandrow syndrome (LSS) [MIM:135750]: A rare
CC       autosomal dominant disorder characterized by polysyndactyly of
CC       hands and/or feet, mirror image duplication of the feet, nasal
CC       defects, and loss of identity between fibula and tibia. Some
CC       patients do not have nasal abnormalities (segmental Laurin-Sandrow
CC       syndrome). {ECO:0000269|PubMed:24456159}. Note=The gene
CC       represented in this entry is involved in disease pathogenesis.
CC       Abnormal SHH limb expression with pathological consequences is
CC       caused by duplications (16-75 kb) involving the ZPA regulatory
CC       sequence (ZRS), a SHH long-range cis-regulatory element, located
CC       in LMBR1 intron 5 (PubMed:24456159).
CC   -!- SIMILARITY: Belongs to the hedgehog family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SHHID378.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/shh/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L38518; AAA62179.1; -; mRNA.
DR   EMBL; AY422195; AAQ87879.1; -; Genomic_DNA.
DR   EMBL; AC002484; AAB67604.1; -; Genomic_DNA.
DR   EMBL; AC078834; AAS01990.1; -; Genomic_DNA.
DR   EMBL; CH236954; EAL23913.1; -; Genomic_DNA.
DR   CCDS; CCDS5942.1; -.
DR   RefSeq; NP_000184.1; NM_000193.2.
DR   UniGene; Hs.164537; -.
DR   PDB; 3HO5; X-ray; 3.01 A; H=29-197.
DR   PDB; 3M1N; X-ray; 1.85 A; A/B=23-197.
DR   PDB; 3MXW; X-ray; 1.83 A; A=29-197.
DR   PDBsum; 3HO5; -.
DR   PDBsum; 3M1N; -.
DR   PDBsum; 3MXW; -.
DR   ProteinModelPortal; Q15465; -.
DR   SMR; Q15465; 25-190, 198-365.
DR   BioGrid; 112365; 5.
DR   STRING; 9606.ENSP00000297261; -.
DR   BindingDB; Q15465; -.
DR   ChEMBL; CHEMBL5602; -.
DR   MEROPS; C46.002; -.
DR   PhosphoSite; Q15465; -.
DR   BioMuta; SHH; -.
DR   DMDM; 6094283; -.
DR   PaxDb; Q15465; -.
DR   PRIDE; Q15465; -.
DR   DNASU; 6469; -.
DR   Ensembl; ENST00000297261; ENSP00000297261; ENSG00000164690.
DR   GeneID; 6469; -.
DR   KEGG; hsa:6469; -.
DR   UCSC; uc003wmj.1; human.
DR   CTD; 6469; -.
DR   GeneCards; GC07M155592; -.
DR   GeneReviews; SHH; -.
DR   HGNC; HGNC:10848; SHH.
DR   HPA; CAB018966; -.
DR   MIM; 135750; phenotype.
DR   MIM; 142945; phenotype.
DR   MIM; 147250; phenotype.
DR   MIM; 174500; phenotype.
DR   MIM; 188740; phenotype.
DR   MIM; 600725; gene.
DR   MIM; 611638; phenotype.
DR   neXtProt; NX_Q15465; -.
DR   Orphanet; 93925; Alobar holoprosencephaly.
DR   Orphanet; 98938; Colobomatous microphthalmia.
DR   Orphanet; 3332; Hypoplastic tibiae - postaxial polydactyly.
DR   Orphanet; 93924; Lobar holoprosencephaly.
DR   Orphanet; 280200; Microform holoprosencephaly.
DR   Orphanet; 93926; Midline interhemispheric variant of holoprosencephaly.
DR   Orphanet; 194; Ocular coloboma.
DR   Orphanet; 295150; Polydactyly of a triphalangeal thumb, bilateral.
DR   Orphanet; 295148; Polydactyly of a triphalangeal thumb, unilateral.
DR   Orphanet; 295071; Radial hemimelia, bilateral.
DR   Orphanet; 295069; Radial hemimelia, unilateral.
DR   Orphanet; 799; Schizencephaly.
DR   Orphanet; 220386; Semilobar holoprosencephaly.
DR   Orphanet; 280195; Septopreoptic holoprosencephaly.
DR   Orphanet; 2286; Solitary median maxillary central incisor syndrome.
DR   Orphanet; 93405; Syndactyly type 4.
DR   Orphanet; 2950; Triphalangeal thumb - polysyndactyly syndrome.
DR   PharmGKB; PA35752; -.
DR   eggNOG; NOG250647; -.
DR   GeneTree; ENSGT00390000001117; -.
DR   HOGENOM; HOG000233428; -.
DR   HOVERGEN; HBG005480; -.
DR   InParanoid; Q15465; -.
DR   KO; K11988; -.
DR   OMA; HSWAHRA; -.
DR   OrthoDB; EOG779NZ5; -.
DR   PhylomeDB; Q15465; -.
DR   TreeFam; TF106458; -.
DR   Reactome; REACT_18372; Class B/2 (Secretin family receptors).
DR   Reactome; REACT_263883; Hh mutants that don't undergo autocatalytic processing are degraded by ERAD.
DR   Reactome; REACT_264256; Release of Hh-Np from the secreting cell.
DR   Reactome; REACT_264605; Hedgehog ligand biogenesis.
DR   Reactome; REACT_268573; Ligand-receptor interactions.
DR   SignaLink; Q15465; -.
DR   ChiTaRS; SHH; human.
DR   EvolutionaryTrace; Q15465; -.
DR   GeneWiki; Sonic_hedgehog; -.
DR   GenomeRNAi; 6469; -.
DR   NextBio; 25129; -.
DR   PRO; PR:Q15465; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; Q15465; -.
DR   CleanEx; HS_SHH; -.
DR   ExpressionAtlas; Q15465; baseline and differential.
DR   Genevisible; Q15465; HS.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005788; C:endoplasmic reticulum lumen; TAS:Reactome.
DR   GO; GO:0005576; C:extracellular region; TAS:Reactome.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0045121; C:membrane raft; ISS:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0005578; C:proteinaceous extracellular matrix; IEA:Ensembl.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0005539; F:glycosaminoglycan binding; IEA:Ensembl.
DR   GO; GO:0043237; F:laminin-1 binding; ISS:UniProtKB.
DR   GO; GO:0016015; F:morphogen activity; NAS:BHF-UCL.
DR   GO; GO:0005113; F:patched binding; IDA:BHF-UCL.
DR   GO; GO:0008233; F:peptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0008209; P:androgen metabolic process; ISS:UniProtKB.
DR   GO; GO:0097190; P:apoptotic signaling pathway; ISS:UniProtKB.
DR   GO; GO:0060840; P:artery development; IEA:Ensembl.
DR   GO; GO:0007411; P:axon guidance; ISS:UniProtKB.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; IEA:Ensembl.
DR   GO; GO:0007596; P:blood coagulation; IEA:Ensembl.
DR   GO; GO:0060445; P:branching involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0001658; P:branching involved in ureteric bud morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048754; P:branching morphogenesis of an epithelial tube; ISS:UniProtKB.
DR   GO; GO:0060447; P:bud outgrowth involved in lung branching; IEA:Ensembl.
DR   GO; GO:0043010; P:camera-type eye development; IEA:Ensembl.
DR   GO; GO:0060070; P:canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0043369; P:CD4-positive or CD8-positive, alpha-beta T cell lineage commitment; IDA:BHF-UCL.
DR   GO; GO:0048468; P:cell development; ISS:UniProtKB.
DR   GO; GO:0001708; P:cell fate specification; ISS:UniProtKB.
DR   GO; GO:0007267; P:cell-cell signaling; ISS:UniProtKB.
DR   GO; GO:0071285; P:cellular response to lithium ion; IEA:Ensembl.
DR   GO; GO:0007417; P:central nervous system development; ISS:UniProtKB.
DR   GO; GO:0021930; P:cerebellar granule cell precursor proliferation; ISS:UniProtKB.
DR   GO; GO:0003140; P:determination of left/right asymmetry in lateral mesoderm; ISS:BHF-UCL.
DR   GO; GO:0021904; P:dorsal/ventral neural tube patterning; IEA:Ensembl.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; ISS:UniProtKB.
DR   GO; GO:0007398; P:ectoderm development; IEA:Ensembl.
DR   GO; GO:0009790; P:embryo development; ISS:UniProtKB.
DR   GO; GO:0048557; P:embryonic digestive tract morphogenesis; IEA:Ensembl.
DR   GO; GO:0042733; P:embryonic digit morphogenesis; ISS:UniProtKB.
DR   GO; GO:0048617; P:embryonic foregut morphogenesis; IEA:Ensembl.
DR   GO; GO:0035115; P:embryonic forelimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0035116; P:embryonic hindlimb morphogenesis; IEA:Ensembl.
DR   GO; GO:0030326; P:embryonic limb morphogenesis; ISS:UniProtKB.
DR   GO; GO:0009880; P:embryonic pattern specification; TAS:BHF-UCL.
DR   GO; GO:0048706; P:embryonic skeletal system development; IEA:Ensembl.
DR   GO; GO:0006897; P:endocytosis; IEA:Ensembl.
DR   GO; GO:0060664; P:epithelial cell proliferation involved in salivary gland morphogenesis; IEA:Ensembl.
DR   GO; GO:0060738; P:epithelial-mesenchymal signaling involved in prostate gland development; IDA:MGI.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; ISS:UniProtKB.
DR   GO; GO:0048859; P:formation of anatomical boundary; IEA:Ensembl.
DR   GO; GO:0031069; P:hair follicle morphogenesis; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; ISS:UniProtKB.
DR   GO; GO:0001947; P:heart looping; ISS:BHF-UCL.
DR   GO; GO:0030902; P:hindbrain development; ISS:UniProtKB.
DR   GO; GO:0007442; P:hindgut morphogenesis; IEA:Ensembl.
DR   GO; GO:0048839; P:inner ear development; IEA:Ensembl.
DR   GO; GO:0016539; P:intein-mediated protein splicing; IEA:InterPro.
DR   GO; GO:0045109; P:intermediate filament organization; IEA:Ensembl.
DR   GO; GO:0060459; P:left lung development; IEA:Ensembl.
DR   GO; GO:0060174; P:limb bud formation; IEA:Ensembl.
DR   GO; GO:0030324; P:lung development; ISS:UniProtKB.
DR   GO; GO:0060428; P:lung epithelium development; IEA:Ensembl.
DR   GO; GO:0060463; P:lung lobe morphogenesis; IEA:Ensembl.
DR   GO; GO:0060484; P:lung-associated mesenchyme development; IEA:Ensembl.
DR   GO; GO:0002320; P:lymphoid progenitor cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0030539; P:male genitalia development; ISS:UniProtKB.
DR   GO; GO:0060916; P:mesenchymal cell proliferation involved in lung development; IEA:Ensembl.
DR   GO; GO:0060783; P:mesenchymal smoothened signaling pathway involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0072136; P:metanephric mesenchymal cell proliferation involved in metanephros development; ISS:UniProtKB.
DR   GO; GO:0001656; P:metanephros development; ISS:UniProtKB.
DR   GO; GO:0030901; P:midbrain development; ISS:UniProtKB.
DR   GO; GO:0080125; P:multicellular structure septum development; IEA:Ensembl.
DR   GO; GO:0045445; P:myoblast differentiation; IEA:Ensembl.
DR   GO; GO:0014902; P:myotube differentiation; IEA:Ensembl.
DR   GO; GO:0046639; P:negative regulation of alpha-beta T cell differentiation; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; ISS:UniProtKB.
DR   GO; GO:0090090; P:negative regulation of canonical Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030336; P:negative regulation of cell migration; ISS:UniProtKB.
DR   GO; GO:0090370; P:negative regulation of cholesterol efflux; ISS:BHF-UCL.
DR   GO; GO:2000357; P:negative regulation of kidney smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:2001054; P:negative regulation of mesenchymal cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0032435; P:negative regulation of proteasomal ubiquitin-dependent protein catabolic process; IEA:Ensembl.
DR   GO; GO:0042130; P:negative regulation of T cell proliferation; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:2000062; P:negative regulation of ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0045060; P:negative thymic T cell selection; ISS:UniProtKB.
DR   GO; GO:0001755; P:neural crest cell migration; ISS:UniProtKB.
DR   GO; GO:0007405; P:neuroblast proliferation; ISS:UniProtKB.
DR   GO; GO:0048663; P:neuron fate commitment; ISS:UniProtKB.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0014003; P:oligodendrocyte development; IEA:Ensembl.
DR   GO; GO:0048645; P:organ formation; IEA:Ensembl.
DR   GO; GO:0002076; P:osteoblast development; IEA:Ensembl.
DR   GO; GO:0060021; P:palate development; IEA:Ensembl.
DR   GO; GO:0031016; P:pancreas development; IEA:Ensembl.
DR   GO; GO:0007389; P:pattern specification process; ISS:UniProtKB.
DR   GO; GO:0001569; P:patterning of blood vessels; ISS:UniProtKB.
DR   GO; GO:0009949; P:polarity specification of anterior/posterior axis; ISS:UniProtKB.
DR   GO; GO:0046638; P:positive regulation of alpha-beta T cell differentiation; ISS:UniProtKB.
DR   GO; GO:0051781; P:positive regulation of cell division; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0060769; P:positive regulation of epithelial cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:0007228; P:positive regulation of hh target transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0033092; P:positive regulation of immature T cell proliferation in thymus; ISS:BHF-UCL.
DR   GO; GO:2000358; P:positive regulation of kidney smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:2000729; P:positive regulation of mesenchymal cell proliferation involved in ureter development; ISS:UniProtKB.
DR   GO; GO:0002052; P:positive regulation of neuroblast proliferation; IEA:Ensembl.
DR   GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IEA:Ensembl.
DR   GO; GO:0061189; P:positive regulation of sclerotome development; IDA:BHF-UCL.
DR   GO; GO:0014858; P:positive regulation of skeletal muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0048643; P:positive regulation of skeletal muscle tissue development; IEA:Ensembl.
DR   GO; GO:0045880; P:positive regulation of smoothened signaling pathway; IDA:UniProtKB.
DR   GO; GO:0051155; P:positive regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0033089; P:positive regulation of T cell differentiation in thymus; ISS:UniProtKB.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; ISS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of transcription, DNA-templated; IDA:BHF-UCL.
DR   GO; GO:2000063; P:positive regulation of ureter smooth muscle cell differentiation; ISS:UniProtKB.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; IEA:Ensembl.
DR   GO; GO:0045059; P:positive thymic T cell selection; ISS:UniProtKB.
DR   GO; GO:0060516; P:primary prostatic bud elongation; IEA:Ensembl.
DR   GO; GO:0060523; P:prostate epithelial cord elongation; IEA:Ensembl.
DR   GO; GO:0030850; P:prostate gland development; ISS:UniProtKB.
DR   GO; GO:0034504; P:protein localization to nucleus; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; ISS:UniProtKB.
DR   GO; GO:0060782; P:regulation of mesenchymal cell proliferation involved in prostate gland development; IEA:Ensembl.
DR   GO; GO:1900175; P:regulation of nodal signaling pathway involved in determination of lateral mesoderm left/right asymmetry; NAS:BHF-UCL.
DR   GO; GO:0042481; P:regulation of odontogenesis; ISS:BHF-UCL.
DR   GO; GO:0060685; P:regulation of prostatic bud formation; IEA:Ensembl.
DR   GO; GO:1900180; P:regulation of protein localization to nucleus; IDA:BHF-UCL.
DR   GO; GO:0030162; P:regulation of proteolysis; ISS:UniProtKB.
DR   GO; GO:0072001; P:renal system development; IEP:UniProtKB.
DR   GO; GO:0060458; P:right lung development; IEA:Ensembl.
DR   GO; GO:0060662; P:salivary gland cavitation; IEA:Ensembl.
DR   GO; GO:0007224; P:smoothened signaling pathway; IEP:UniProtKB.
DR   GO; GO:0021938; P:smoothened signaling pathway involved in regulation of cerebellar granule cell precursor cell proliferation; IEA:Ensembl.
DR   GO; GO:0061053; P:somite development; ISS:BHF-UCL.
DR   GO; GO:0021522; P:spinal cord motor neuron differentiation; IEA:Ensembl.
DR   GO; GO:0048864; P:stem cell development; ISS:UniProtKB.
DR   GO; GO:0014706; P:striated muscle tissue development; IEA:Ensembl.
DR   GO; GO:0033077; P:T cell differentiation in thymus; ISS:BHF-UCL.
DR   GO; GO:0021978; P:telencephalon regionalization; IEA:Ensembl.
DR   GO; GO:0021794; P:thalamus development; IEA:Ensembl.
DR   GO; GO:0048538; P:thymus development; ISS:UniProtKB.
DR   GO; GO:0030878; P:thyroid gland development; IEA:Ensembl.
DR   GO; GO:0060439; P:trachea morphogenesis; IEA:Ensembl.
DR   GO; GO:0001570; P:vasculogenesis; ISS:UniProtKB.
DR   GO; GO:0007418; P:ventral midline development; TAS:BHF-UCL.
DR   Gene3D; 2.170.16.10; -; 1.
DR   Gene3D; 3.30.1380.10; -; 1.
DR   InterPro; IPR001657; Hedgehog.
DR   InterPro; IPR028992; Hedgehog/Intein_dom.
DR   InterPro; IPR009045; Hedgehog_sig/DD-Pept_Zn-bd_dom.
DR   InterPro; IPR000320; Hedgehog_signalling_dom.
DR   InterPro; IPR001767; Hint_dom.
DR   InterPro; IPR003586; Hint_dom_C.
DR   InterPro; IPR003587; Hint_dom_N.
DR   InterPro; IPR006141; Intein_N.
DR   Pfam; PF01085; HH_signal; 1.
DR   Pfam; PF01079; Hint; 1.
DR   PIRSF; PIRSF009400; Peptidase_C46; 1.
DR   PRINTS; PR00632; SONICHHOG.
DR   SMART; SM00305; HintC; 1.
DR   SMART; SM00306; HintN; 1.
DR   SUPFAM; SSF51294; SSF51294; 1.
DR   SUPFAM; SSF55166; SSF55166; 1.
DR   PROSITE; PS50817; INTEIN_N_TER; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Autocatalytic cleavage; Calcium; Cell membrane;
KW   Complete proteome; Developmental protein; Direct protein sequencing;
KW   Disease mutation; Glycoprotein; Holoprosencephaly; Hydrolase;
KW   Lipoprotein; Membrane; Metal-binding; Microphthalmia; Palmitate;
KW   Protease; Reference proteome; Secreted; Signal; Zinc.
FT   SIGNAL        1     23       {ECO:0000269|PubMed:9593755}.
FT   CHAIN        24    462       Sonic hedgehog protein.
FT                                /FTId=PRO_0000013208.
FT   CHAIN        24    197       Sonic hedgehog protein N-product.
FT                                /FTId=PRO_0000013209.
FT   CHAIN       198    462       Sonic hedgehog protein C-product.
FT                                /FTId=PRO_0000013210.
FT   COMPBIAS    407    411       Poly-Gly.
FT   METAL        89     89       Calcium 1.
FT   METAL        90     90       Calcium 1.
FT   METAL        90     90       Calcium 2.
FT   METAL        95     95       Calcium 1.
FT   METAL       125    125       Calcium 1; via carbonyl oxygen.
FT   METAL       126    126       Calcium 1.
FT   METAL       126    126       Calcium 2.
FT   METAL       129    129       Calcium 2.
FT   METAL       131    131       Calcium 2.
FT   METAL       140    140       Zinc. {ECO:0000269|PubMed:19561609,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       147    147       Zinc. {ECO:0000269|PubMed:19561609,
FT                                ECO:0000269|PubMed:20504762}.
FT   METAL       182    182       Zinc. {ECO:0000269|PubMed:19561609,
FT                                ECO:0000269|PubMed:20504762}.
FT   SITE        197    198       Cleavage; by autolysis. {ECO:0000250}.
FT   SITE        243    243       Involved in cholesterol transfer.
FT                                {ECO:0000250}.
FT   SITE        267    267       Involved in auto-cleavage. {ECO:0000250}.
FT   SITE        270    270       Essential for auto-cleavage.
FT                                {ECO:0000250}.
FT   LIPID        24     24       N-palmitoyl cysteine.
FT                                {ECO:0000269|PubMed:9593755}.
FT   LIPID       197    197       Cholesterol glycine ester. {ECO:0000250}.
FT   CARBOHYD    278    278       N-linked (GlcNAc...).
FT                                {ECO:0000269|PubMed:16335952}.
FT   VARIANT       6      6       R -> T (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023804.
FT   VARIANT      17     17       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062592.
FT   VARIANT      26     26       P -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062593.
FT   VARIANT      27     27       G -> A (in HPE3).
FT                                {ECO:0000269|PubMed:15107988,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039888.
FT   VARIANT      31     31       G -> R (in HPE3; the same mutation in the
FT                                mouse sequence introduces a cleavage site
FT                                for a furin-like protease resulting in
FT                                abnormal protein processing; cleavage at
FT                                this site removes 11 amino acids from the
FT                                N-terminal domain and reduces affinity of
FT                                Shh for Ptch1 and signaling potency in
FT                                assays using chicken embryo neural plate
FT                                explants and mouse C3H10T1/2 stem cells;
FT                                dbSNP:rs28936675).
FT                                {ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:8896572,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_003619.
FT   VARIANT      39     39       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062594.
FT   VARIANT      53     53       E -> K (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062595.
FT   VARIANT      83     83       D -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062596.
FT   VARIANT      84     84       I -> F (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062597.
FT   VARIANT      88     88       D -> V (in HPE3; familial; the same
FT                                mutation in the mouse sequence moderately
FT                                reduces Ptch1 binding in vitro and
FT                                signaling potency in chicken embryo
FT                                neural plate explant assays compared with
FT                                wild-type sequence).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009163.
FT   VARIANT     100    100       Q -> H (in HPE3; sporadic; in the mouse
FT                                sequence does not affect signaling
FT                                activity in any of Shh signaling assays
FT                                and causes no apparent defects in
FT                                cholesterol-mediated autoprocessing
FT                                reactions). {ECO:0000269|PubMed:10441331,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009164.
FT   VARIANT     102    102       C -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062598.
FT   VARIANT     102    102       C -> Y (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062599.
FT   VARIANT     106    107       Missing (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023805.
FT   VARIANT     109    109       L -> F (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062600.
FT   VARIANT     110    110       A -> D (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023806.
FT   VARIANT     110    110       A -> T (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062601.
FT   VARIANT     111    111       I -> F (in SMMCI).
FT                                {ECO:0000269|PubMed:11471164,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_017883.
FT   VARIANT     111    111       I -> N (in HPE3).
FT                                {ECO:0000269|PubMed:15942952,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039889.
FT   VARIANT     115    115       N -> K (in HPE3; familial; in the mouse
FT                                sequence shows no change in activities at
FT                                different temperatures).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009165.
FT   VARIANT     117    117       W -> G (in HPE3; the same mutation in the
FT                                mouse sequence causes a failure of Shh
FT                                processing leading to retention of the
FT                                immature glycosylated protein within the
FT                                endoplasmic reticulum of transfected
FT                                cells; causes a temperature-dependent
FT                                conformational change that allows Shh to
FT                                bind Ptch1 at 4 or 32 degrees Celsius but
FT                                not at 37 degrees Celsius; the mutation
FT                                drastically reduces signaling potency in
FT                                chicken embryo neural plate explant
FT                                assays). {ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:8896572,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_003620.
FT   VARIANT     117    117       W -> R (in HPE3; the same mutation in the
FT                                mouse sequence causes a failure of Shh
FT                                processing leading to retention of the
FT                                immature glycosylated protein within the
FT                                endoplasmic reticulum of transfected
FT                                cells; causes a temperature-dependent
FT                                conformational change that allows Shh to
FT                                bind Ptch1 at 4 or 32 degrees Celsius but
FT                                not at 37 degrees Celsius; drastically
FT                                reduces signaling potency in chicken
FT                                embryo neural plate explant assays).
FT                                {ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:8896572,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_003621.
FT   VARIANT     124    124       V -> M (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062602.
FT   VARIANT     136    136       E -> K (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062603.
FT   VARIANT     140    140       H -> P (in HPE3).
FT                                {ECO:0000269|PubMed:11479728,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039890.
FT   VARIANT     140    140       H -> Q (in HPE3).
FT                                {ECO:0000269|PubMed:15942953,
FT                                ECO:0000269|PubMed:17001669,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039891.
FT   VARIANT     143    143       G -> D (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062604.
FT   VARIANT     144    144       R -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062605.
FT   VARIANT     147    147       D -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062606.
FT   VARIANT     150    150       T -> K (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062607.
FT   VARIANT     150    150       T -> R (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023807.
FT   VARIANT     156    156       S -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062608.
FT   VARIANT     170    170       F -> C (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062609.
FT   VARIANT     171    171       D -> H (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062610.
FT   VARIANT     176    178       Missing (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023808.
FT   VARIANT     183    183       C -> F (in HPE3).
FT                                {ECO:0000269|PubMed:11479728,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039892.
FT   VARIANT     183    183       C -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062611.
FT   VARIANT     183    183       C -> Y (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062612.
FT   VARIANT     184    184       S -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062613.
FT   VARIANT     188    188       E -> Q (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10441331,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:16282375,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009166.
FT   VARIANT     196    200       Missing (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062614.
FT   VARIANT     196    196       G -> E (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062615.
FT   VARIANT     197    197       G -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062616.
FT   VARIANT     198    198       C -> F (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062617.
FT   VARIANT     198    198       C -> S (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062618.
FT   VARIANT     218    218       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:17001669,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062619.
FT   VARIANT     222    222       D -> N (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10441331,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009167.
FT   VARIANT     224    224       V -> E (in HPE3).
FT                                {ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_009168.
FT   VARIANT     226    226       A -> T (in HPE3; familial).
FT                                {ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_009169.
FT   VARIANT     231    231       G -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062620.
FT   VARIANT     232    232       R -> G (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062621.
FT   VARIANT     234    234       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062622.
FT   VARIANT     236    236       S -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062623.
FT   VARIANT     236    236       S -> R (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009170.
FT   VARIANT     241    241       F -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062624.
FT   VARIANT     241    241       F -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062625.
FT   VARIANT     255    255       I -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062626.
FT   VARIANT     263    269       Missing (in HPE3; sporadic).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009171.
FT   VARIANT     267    267       T -> I (in HPE3).
FT                                {ECO:0000269|PubMed:15107988,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039893.
FT   VARIANT     271    271       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023809.
FT   VARIANT     275    275       A -> E (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062627.
FT   VARIANT     280    280       S -> W (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062628.
FT   VARIANT     290    290       G -> D (in HPE3; sporadic;
FT                                dbSNP:rs104894047).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009172.
FT   VARIANT     296    296       G -> A (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062629.
FT   VARIANT     310    310       R -> C (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062630.
FT   VARIANT     321    321       R -> S (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062631.
FT   VARIANT     332    332       V -> A (in HPE3 and SMMCI).
FT                                {ECO:0000269|PubMed:15103725,
FT                                ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023810.
FT   VARIANT     346    346       A -> V (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062632.
FT   VARIANT     347    347       P -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062633.
FT   VARIANT     347    347       P -> Q (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023811.
FT   VARIANT     347    347       P -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062634.
FT   VARIANT     354    354       I -> T (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023812.
FT   VARIANT     362    362       S -> L (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062635.
FT   VARIANT     363    363       C -> Y (in HPE3).
FT                                {ECO:0000269|PubMed:17001669,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062636.
FT   VARIANT     364    364       Y -> C (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062637.
FT   VARIANT     373    373       A -> T (in HPE3).
FT                                {ECO:0000269|PubMed:15107988,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_039894.
FT   VARIANT     374    374       H -> R (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062638.
FT   VARIANT     376    376       A -> D (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062639.
FT   VARIANT     377    377       F -> S (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062640.
FT   VARIANT     378    380       Missing (in HPE3; familial).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009173.
FT   VARIANT     381    381       R -> P (in HPE3).
FT                                {ECO:0000269|PubMed:15221788,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_023813.
FT   VARIANT     382    382       L -> P (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062641.
FT   VARIANT     383    383       A -> T (in HPE3; sporadic).
FT                                {ECO:0000269|PubMed:19603532,
FT                                ECO:0000269|PubMed:9302262}.
FT                                /FTId=VAR_009174.
FT   VARIANT     391    391       A -> T (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062642.
FT   VARIANT     401    408       Missing (in ocular coloboma).
FT                                {ECO:0000269|PubMed:12503095}.
FT                                /FTId=VAR_017884.
FT   VARIANT     402    409       Missing (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062643.
FT   VARIANT     404    408       Missing (in HPE3; familial).
FT                                /FTId=VAR_009175.
FT   VARIANT     405    409       Missing (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062644.
FT   VARIANT     411    411       G -> GG (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062645.
FT   VARIANT     416    416       T -> A (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062646.
FT   VARIANT     424    424       P -> A (in HPE3; familial).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009176.
FT   VARIANT     435    435       Y -> N (in HPE3).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062647.
FT   VARIANT     436    436       S -> L (in HPE3; sporadic).
FT                                {ECO:0000269|PubMed:10556296,
FT                                ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_009177.
FT   VARIANT     456    456       G -> R (in HPE3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19603532}.
FT                                /FTId=VAR_062648.
FT   MUTAGEN      24     24       C->S: Abolishes palmitoylation.
FT                                {ECO:0000269|PubMed:9593755}.
FT   STRAND       30     32       {ECO:0000244|PDB:3M1N}.
FT   STRAND       47     51       {ECO:0000244|PDB:3MXW}.
FT   TURN         56     59       {ECO:0000244|PDB:3MXW}.
FT   HELIX        72     75       {ECO:0000244|PDB:3MXW}.
FT   STRAND       84     86       {ECO:0000244|PDB:3MXW}.
FT   STRAND       91     93       {ECO:0000244|PDB:3MXW}.
FT   HELIX        94     96       {ECO:0000244|PDB:3MXW}.
FT   HELIX       100    116       {ECO:0000244|PDB:3MXW}.
FT   STRAND      122    128       {ECO:0000244|PDB:3MXW}.
FT   HELIX       139    142       {ECO:0000244|PDB:3MXW}.
FT   STRAND      145    150       {ECO:0000244|PDB:3MXW}.
FT   HELIX       155    157       {ECO:0000244|PDB:3MXW}.
FT   HELIX       158    167       {ECO:0000244|PDB:3MXW}.
FT   STRAND      171    177       {ECO:0000244|PDB:3MXW}.
FT   STRAND      180    184       {ECO:0000244|PDB:3MXW}.
FT   HELIX       188    190       {ECO:0000244|PDB:3MXW}.
SQ   SEQUENCE   462 AA;  49607 MW;  DD687AFA582A4749 CRC64;
     MLLLARCLLL VLVSSLLVCS GLACGPGRGF GKRRHPKKLT PLAYKQFIPN VAEKTLGASG
     RYEGKISRNS ERFKELTPNY NPDIIFKDEE NTGADRLMTQ RCKDKLNALA ISVMNQWPGV
     KLRVTEGWDE DGHHSEESLH YEGRAVDITT SDRDRSKYGM LARLAVEAGF DWVYYESKAH
     IHCSVKAENS VAAKSGGCFP GSATVHLEQG GTKLVKDLSP GDRVLAADDQ GRLLYSDFLT
     FLDRDDGAKK VFYVIETREP RERLLLTAAH LLFVAPHNDS ATGEPEASSG SGPPSGGALG
     PRALFASRVR PGQRVYVVAE RDGDRRLLPA AVHSVTLSEE AAGAYAPLTA QGTILINRVL
     ASCYAVIEEH SWAHRAFAPF RLAHALLAAL APARTDRGGD SGGGDRGGGG GRVALTAPGA
     ADAPGAGATA GIHWYSQLLY QIGTWLLDSE ALHPLGMAVK SS
//
